ArticlePLoS pathogens2025
Pattern recognition receptor-associated immuno-thrombotic transcript changes in platelets and leukocytes with COVID19.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Altered Erythrocyte Function via TLR9-ox-mtDNA Binding Links Mitochondrial Oxidative Damage to Systemic Inflammation in Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Pattern Recognition Receptors (PRRs) Expression and Activation in COVID-19 and Long COVID: From SARS-CoV-2 Escape Mechanisms to Emerging PRR-Targeted Immunotherapies.Microorganisms · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Respiratory infections are characterized by an increased risk of thrombosis, likely involving platelet-leukocyte crosstalk via pattern recognition receptors (PRRs). Here we characterized COVID19-mediated changes in PRR levels and their associations with thrombotic/coagulation-related transcriptional programs across platelets and leukocytes and assessed their correlation with COVID19 outcomes. Amplicon RNAseq of platelets and leukocytes from COVID19 patients (n = 10) and non-infected donors (n = 15) showed distinct patterns of PRR-expression levels based on cell type. Platelets from non-infected donors expressed TLR9 > RIG-I> CGAS at the highest level while leukocytes expressed TLR4 > TLR8 > RIG-I. COVID19 resulted in increased levels of TLR9, RIG-I, CGAS, and TLR1 in platelets and decreased levels of TLR6 and TLR8 in leukocytes, while the levels of the highest expressed PRRs remained almost unchanged. In platelets from COVID19 patients, MDA5, RIG-I, and LGP2 showed the highest associations with thrombotic-, coagulation-, and thrombolysis-associated transcripts, while in non-infected donors, TLR9 showed the highest associations with those transcripts. In leukocytes, RIG-I and MDA5 also correlated with coagulation-related transcripts when derived from the non-infected donors, but those associations were almost lost with COVID19. Platelet-leukocyte aggregates increased with COVID19 as did extracellular vesicles detected by imaging cytometry, immunofluorescence, or electron microscopy. Platelet-TLR3 and leukocyte-TLR5 positively correlated with severity and survival of the COVID19 patients, while leukocyte-TLR7 showed an inverse correlation. Coagulopathy, measured by INR, was associated with platelet-TLR4 and leukocyte-TLR10. Liver inflammation, assessed by ALT levels, correlated with platelet- and leukocyte-LGP2, in addition to leukocyte-TLR3, -TLR6, -TLR7, and -RIG-I. Analysis of publicly available whole-blood-RNAseq, showed that COVID19 and tuberculosis were more similar than COVID19 and influenza with respect to associations between PRRs and thrombotic/coagulation-related transcripts. Overall, platelets and leukocytes exhibit distinct patterns of PRR expression and correlations with thrombotic/coagulation-related transcripts that change with COVID19, and there are distinct PRRs in each cell population that associate with COVID19 severity, coagulopathy, and liver damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.